The Cutting Ball Theater
| Address | 277 Taylor St San Francisco United States |
|---|---|
| Type | Theatre company |
| Construction | |
| Opened | 1999 |
| Closed | 2024 |
Years active | 1999–2024 |
Cutting Ball Theater was a San Francisco-based theater company.[1] New works performed by Cutting Ball include Bay Area premieres by American playwrights Will Eno[2] and Eugenie Chan.[3] The company closed at the end of 2024.[4]
History
The company was founded in 1999 by theater artist Rob Melrose and artistic director Paige Rogers.[5] The theater, which ran as a collective, closed in 2024 during a series of theater closures in the area. The attendance impacts from the COVID pandemic and the decrease in available grant funding were given as reasons for the demise.[4]
Productions
Cutting Ball Theater premiered and produced a variety of plays, including:
Awards and recognition
In 2010, Cutting Ball Theater was named "Best Theater Company" in the San Francisco Bay Guardian's "Best of the Bay" issue.[8]
In 2013, the company received the American Theatre Wing's National Theatre Company Grant.[9]
References
- ↑ Member Companies section of Theatre Bay Area
- ↑ Review of "Lady Grey in ever lower light" in San Francisco Chronicle, March 19, 2011
- ↑ Review of "Bone to Pick" and "Diadem" in San Francisco Chronicle, January 22, 2011
- 1 2 Gluckstern, Nicole (July 19, 2024). "Farewell to Cutting Ball Theater, a Bastion of Fearless Experimentation". KQED. Retrieved August 4, 2026.
- ↑ About Us on Cuttingball.com
- ↑ Hurwitt, Robert (March 19, 2011). "Review: 'Lady Grey' in ever lower light". San Francisco Chronicle. Retrieved October 10, 2023.
- ↑ Hurwitt, Robert (January 22, 2011). "Review: 'Bone to Pick' and 'Diadem'". San Francisco Chronicle. Retrieved October 10, 2023.
- ↑ "Best of the Bay 2010: Arts and Nightlife". San Francisco Bay Guardian. 2010. Retrieved October 10, 2023.
- ↑ "American Theatre Wing Announces Recipients of 2013 National Theatre Company Grants". StageLight Magazine. September 3, 2013. Retrieved October 10, 2023.